At what enterprise value was CERBA HEALTHCARE acquired in 2021?

During the acquisition of CERBA HEALTHCARE by EQT PARTNERS in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CERBA HEALTHCARE when it was acquired by EQT PARTNERS?

The estimated EV/EBITDA multiple for CERBA HEALTHCARE is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was CERBA HEALTHCARE acquired by EQT PARTNERS?

CERBA HEALTHCARE was acquired by EQT PARTNERS in 2021.

What was the revenue of CERBA HEALTHCARE at the time of the deal?

The revenue of CERBA HEALTHCARE at the time of the deal is estimated to be in the range of 1b - 3b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of CERBA HEALTHCARE during the acquisition?

CERBA HEALTHCARE's EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CERBA HEALTHCARE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CERBA HEALTHCARE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.investpsp.com/fr/nouvelles/cerba-healthcare-accueille-eqt-comme-nouvel-actionnaire-pour-favoriser-linnovation-et-toujours-mieux-repondre-aux-nouveaux-enjeux-de-la-sante/

← DATABASE

Home Database Healthcare & PharmaCERBA HEALTHCARE

03/2021

CERBA HEALTHCARE acquired by EQT PARTNERS

FRANCE Health Providers / Healthcare Facilities / Labs (Biology) EV 3b - 100b EUR

Context

EQT entered into exclusive negotiations to acquire Cerba HealthCare from Partners Group. The transaction values the group at EUR4.5 billion, significantly higher than initial market estimates (EUR3bn). PSP Investments, a shareholder for four years, realized a partial cash-out but reinvested to remain a key minority partner alongside EQT and the 400 biologist-managers. The deal was financed with a massive EUR2.5 billion Senior Debt package (Term Loan B).

Previously, the company had already undergone several LBOs, notably led by Pai Partners in 2010 and Partners Group / Psp Investments in 2017. This succession of buyouts, combined with an active build-up strategy, highlights the strong attractiveness of the company's business model.

CERBA HEALTHCARE, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Cerba HealthCare is a leading international network of clinical pathology laboratories. Headquartered in France, it operates across Europe and Africa. The group serves patients, physicians, and pharmaceutical companies (via its clinical trial division). It relies on a network of 400 biologists and managers who are also shareholders.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Other operations with CERBA HEALTHCARE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	CRO / Clinical Trials
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
07/2021	CERBA HEALTHCARE	LIFEBRAIN	ITALY	Labs (Biology)
01/2017	PARTNERS GROUP / PSP INVESTMENTS	CERBA HEALTHCARE	FRANCE	Labs (Biology)
01/2015	CERBA HEALTHCARE	NOVESCIA	FRANCE	Labs (Biology)
06/2010	PAI PARTNERS	CERBA HEALTHCARE	FRANCE	Labs (Biology)

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 1b - 3b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CERBA HEALTHCARE by EQT PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: cerba healthcare

Acquirer: eqt partners